Published in Oncology (Williston Park) on June 01, 2014
Expansion and patterning of cardiovascular progenitors derived from human pluripotent stem cells. Nat Biotechnol (2015) 1.22
Cardiovascular toxicity of Newer chemotherapeutic agents: the heart of the matter. Oncology (Williston Park) (2014) 0.75
Cardiotoxicity of targeted agents in oncology: a medical oncology perspective. Oncology (Williston Park) (2014) 0.75
Cardiac dysfunction among soft tissue sarcoma patients in Denmark. Clin Epidemiol (2016) 0.75
Revised response criteria for malignant lymphoma. J Clin Oncol (2007) 22.19
T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci U S A (2008) 4.74
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Multiplexed detection of protein cancer markers with biobarcoded nanoparticle probes. J Am Chem Soc (2006) 2.64
Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options. Oncology (Williston Park) (2010) 2.41
Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril (2002) 2.22
Peripheral T-cell lymphoma. Blood (2011) 2.11
Peripheral T-cell lymphoma: new therapeutic strategies. Oncology (Williston Park) (2013) 2.09
Acquired hemophilia a: diagnosis, aetiology, clinical spectrum and treatment options. Autoimmun Rev (2010) 1.90
A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. Br J Haematol (2007) 1.72
Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp Hematol (2003) 1.55
T-cell non-Hodgkin lymphoma. Blood (2005) 1.53
Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin Cancer Res (2002) 1.48
Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes. Leuk Lymphoma (2014) 1.47
Combination treatment of vertebral metastases using image-guided percutaneous radiofrequency ablation and vertebroplasty: a case report. Surg Neurol (2005) 1.46
Cancer metabolism as a therapeutic target. Oncology (Williston Park) (2013) 1.46
CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- disease. Am J Clin Pathol (2008) 1.44
Clinical Management Updates in Mantle Cell Lymphoma. Oncology (Williston Park) (2016) 1.43
Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 2: adoptive cellular immunotherapy, small-molecule inhibitors, and immunomodulation. Oncology (Williston Park) (2015) 1.42
Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 1. Oncology (Williston Park) (2015) 1.40
Mechanisms of glucocorticoid-induced apoptosis in hematologic malignancies: updates. Curr Opin Oncol (2004) 1.38
Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol (2012) 1.28
Lipid encapsulation of arsenic trioxide attenuates cytotoxicity and allows for controlled anticancer drug release. J Am Chem Soc (2006) 1.27
Glucose transporters in cancer metabolism. Curr Opin Oncol (2012) 1.25
Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy. Blood (2012) 1.13
Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther (2006) 1.09
The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol (2006) 1.05
Steroid receptor and microRNA regulation in cancer. Curr Opin Oncol (2010) 1.04
Coencapsulation of arsenic- and platinum-based drugs for targeted cancer treatment. Angew Chem Int Ed Engl (2009) 1.04
8-Amino-adenosine induces loss of phosphorylation of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2, and Akt kinase: role in induction of apoptosis in multiple myeloma. Mol Cancer Ther (2005) 1.04
Targeting glucose consumption and autophagy in myeloma with the novel nucleoside analogue 8-aminoadenosine. J Biol Chem (2009) 1.03
Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. Hepatology (2012) 1.03
β-Catenin induces T-cell transformation by promoting genomic instability. Proc Natl Acad Sci U S A (2013) 1.03
A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma (2004) 1.02
Primary cutaneous CD30+ lymphoproliferative disorders: new insights into biology and therapy. Oncology (Williston Park) (2007) 1.02
The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy. Curr Opin Hematol (2005) 1.01
Dual regulation of glucocorticoid-induced leucine zipper (GILZ) by the glucocorticoid receptor and the PI3-kinase/AKT pathways in multiple myeloma. J Steroid Biochem Mol Biol (2008) 0.99
Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center. Leuk Lymphoma (2009) 0.98
Enzastaurin. Curr Opin Oncol (2007) 0.96
8-amino-adenosine is a potential therapeutic agent for multiple myeloma. Mol Cancer Ther (2004) 0.94
The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies. J Am Acad Dermatol (2011) 0.94
Chronic lymphocytic leukemia FISH panel: impact on diagnosis. Am J Clin Pathol (2007) 0.93
Cutaneous T-cell lymphomas: a review of new discoveries and treatments. Curr Treat Options Oncol (2012) 0.92
Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol (2005) 0.92
8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma. Blood (2010) 0.92
Inhibition of ATP synthase by chlorinated adenosine analogue. Biochem Pharmacol (2009) 0.91
Role for microRNAs in regulating glucocorticoid response and resistance in multiple myeloma. Horm Cancer (2011) 0.90
Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys (2012) 0.89
Using the bioconductor GeneAnswers package to interpret gene lists. Methods Mol Biol (2012) 0.89
Targeting the Warburg effect in hematological malignancies: from PET to therapy. Curr Opin Oncol (2009) 0.89
A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas. Br J Haematol (2013) 0.88
Glucocorticoid receptor transcriptional isoforms and resistance in multiple myeloma cells. Mol Cancer Ther (2006) 0.88
Bexarotene in the treatment of cutaneous T-cell lymphoma. Expert Opin Pharmacother (2006) 0.88
Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma. Leuk Lymphoma (2011) 0.87
Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O⁶-methylguanine-DNA methyltransferase and mismatch repair proteins. Clin Cancer Res (2011) 0.86
Signal transduction inhibitors in chronic lymphocytic leukemia. Curr Opin Oncol (2011) 0.85
Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. Leuk Lymphoma (2014) 0.84
Caspase activation is required for gemcitabine activity in multiple myeloma cell lines. Mol Cancer Ther (2002) 0.84
Primary cutaneous lymphomas: a review with current treatment options. Blood Rev (2003) 0.84
Inhibition of glycogen synthase kinase-3 increases the cytotoxicity of enzastaurin. J Invest Dermatol (2011) 0.82
Multiple successful desensitizations to brentuximab vedotin: a case report and literature review. J Natl Compr Canc Netw (2014) 0.82
8-Amino-adenosine activates p53-independent cell death of metastatic breast cancers. Mol Cancer Ther (2012) 0.81
Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome. Blood (2013) 0.81
Cutaneous involvement with marginal zone lymphoma. J Am Acad Dermatol (2010) 0.80
Association of serum triiodothyronine with B-type natriuretic peptide and severe left ventricular diastolic dysfunction in heart failure with preserved ejection fraction. Am J Cardiol (2012) 0.80
Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma. J Am Acad Dermatol (2004) 0.80
Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms. PLoS One (2012) 0.80
An update on the risk prediction and prevention of anticancer therapy-induced cardiotoxicity. Curr Opin Oncol (2014) 0.79
Investigating and targeting chronic lymphocytic leukemia metabolism with the human immunodeficiency virus protease inhibitor ritonavir and metformin. Leuk Lymphoma (2014) 0.79
In vitro assessment of nucleoside analogs in multiple myeloma. Cancer Chemother Pharmacol (2004) 0.78
T-cell non-Hogdkin's lymphoma. Cancer Treat Res (2006) 0.78
Challenges of multiple mutations in individual patients with haemophilia. Eur J Haematol (2011) 0.78
Expression and phosphorylation of the AS160_v2 splice variant supports GLUT4 activation and the Warburg effect in multiple myeloma. Cancer Metab (2013) 0.78
Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies. Cell Cycle (2012) 0.77
The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial. Clin Cancer Res (2009) 0.77
Tumor microenvironment in mycosis fungoides and Sézary syndrome. Curr Opin Oncol (2016) 0.76
Clinical perspective on chemo-resistance and the role of RNA processing. Cancer Treat Res (2013) 0.76
Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia. Semin Oncol (2002) 0.76
Current status of monoclonal antibody therapy for chronic lymphocytic leukemia. Oncology (Williston Park) (2003) 0.76
Cutaneous T-cell lymphomas: a review with emphasis on new treatment approaches. Semin Cutan Med Surg (2003) 0.75
An Elderly Man With New Skin Plaques Consistent With Cutaneous T-Cell Lymphoma. Oncology (Williston Park) (2016) 0.75
Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia. Semin Oncol (2002) 0.75
Secondary cutaneous anaplastic large cell lymphoma treated with liposomal doxorubicin (Doxil) leading to complete remission. Int J Dermatol (2003) 0.75
High-dose therapy and bone marrow transplantation in cutaneous T-cell lymphoma. Hematol Oncol Clin North Am (2003) 0.75
Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and Sézary syndrome. J Am Acad Dermatol (2006) 0.75